These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 11948131

  • 1. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzoni P, Riva A, Giavazzi R.
    Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
    [Abstract] [Full Text] [Related]

  • 2. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F.
    Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
    Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, Morazzoni P, Zucchetti M.
    Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
    [Abstract] [Full Text] [Related]

  • 4. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
    Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F.
    Br J Cancer; 2004 Apr 05; 90(7):1464-8. PubMed ID: 15054472
    [Abstract] [Full Text] [Related]

  • 5. IDN 5390: an oral taxane candidate for protracted treatment schedules.
    Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, Riva A, Zunino F.
    Br J Cancer; 2003 Mar 24; 88(6):965-72. PubMed ID: 12644838
    [Abstract] [Full Text] [Related]

  • 6. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
    Grant DS, Williams TL, Zahaczewsky M, Dicker AP.
    Int J Cancer; 2003 Mar 10; 104(1):121-9. PubMed ID: 12532428
    [Abstract] [Full Text] [Related]

  • 7. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
    Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ.
    J Natl Cancer Inst; 2001 Aug 15; 93(16):1234-45. PubMed ID: 11504769
    [Abstract] [Full Text] [Related]

  • 8. IDN 5390: a new concept in taxane development.
    Taraboletti G, Micheletti G, Giavazzi R, Riva A.
    Anticancer Drugs; 2003 Apr 15; 14(4):255-8. PubMed ID: 12679728
    [Abstract] [Full Text] [Related]

  • 9. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
    Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL.
    Mol Cancer Ther; 2002 Nov 15; 1(13):1191-200. PubMed ID: 12479700
    [Abstract] [Full Text] [Related]

  • 11. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
    Ojo-Amaize EA, Nchekwube EJ, Cottam HB, Bai R, Verdier-Pinard P, Kakkanaiah VN, Varner JA, Leoni L, Okogun JI, Adesomoju AA, Oyemade OA, Hamel E.
    Cancer Res; 2002 Jul 15; 62(14):4007-14. PubMed ID: 12124334
    [Abstract] [Full Text] [Related]

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 13. Oral efficacy and bioavailability of a novel taxane.
    Polizzi D, Pratesi G, Monestiroli S, Tortoreto M, Zunino F, Bombardelli E, Riva A, Morazzoni P, Colombo T, D'Incalci M, Zucchetti M.
    Clin Cancer Res; 2000 May 15; 6(5):2070-4. PubMed ID: 10815934
    [Abstract] [Full Text] [Related]

  • 14. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
    Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW.
    Cancer Res; 2001 Apr 15; 61(8):3369-72. PubMed ID: 11309294
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
    Chen HH, Zhou HJ, Wu GD, Lou XE.
    Pharmacology; 2004 May 15; 71(1):1-9. PubMed ID: 15051917
    [Abstract] [Full Text] [Related]

  • 16. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
    Yeh CH, Peng HC, Yang RS, Huang TF.
    Mol Pharmacol; 2001 May 15; 59(5):1333-42. PubMed ID: 11306719
    [Abstract] [Full Text] [Related]

  • 17. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA, Robinson C, Angeles T, Wilkinson J, Clapper ML.
    Clin Cancer Res; 2002 Jan 15; 8(1):267-74. PubMed ID: 11801568
    [Abstract] [Full Text] [Related]

  • 18. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
    Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F.
    Int J Cancer; 2001 Jun 01; 92(5):738-47. PubMed ID: 11340581
    [Abstract] [Full Text] [Related]

  • 19. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
    Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4331-8. PubMed ID: 16857808
    [Abstract] [Full Text] [Related]

  • 20. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.